The present invention proposes the method for identifying novel piRNA signatures which is considered as the over-expressed group of piRNAs to distinguish between healthy and Alzheimer’s affected human brain. Next-generation small RNA sequencing of size- fractionated RNAs of 16-36 nucleotides (nts) is performed to visualize and identify the presence of piRNAs in normal as well as the AD-affected brain. The study identified piRNAs in these samples as well as a catalog of significantly dysregulated piRNAs in AD. The functional roles of these dysregulated piRNAs are assessed by enrichment of disease-specific biological pathways mediated by these players.
展开▼
